6th Apr 2020 09:30
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
VISITECT® CD4 Advanced Disease evaluation in
Malawi, Zimbabwe and the Democratic Republic of Congo
Omega (AIM: ODX), the medical diagnostics company focused on CD4, food intolerance and allergy testing notes the publication on 3 April 2020 of the two phased diagnostic accuracy and feasibility-of-use evaluation study, conducted in Médecins Sans Frontiéres (MSF) supported health facilities in Malawi, Zimbabwe and the Democratic Republic of Congo.
The evaluation, led by Zibusiso Ndlovu of MSF's Southern Africa Medical Unit in Cape Town, South Africa concluded that Omega's VISITECT® CD4 Advanced Disease lateral flow assay is a promising test for decentralised CD4 screening in resource-limited settings, without access to CD4 testing and it can trigger prompt management of patients with Advanced HIV Disease.
The full research articles can be accessed from the following weblink:
https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0230453&type=printable
Contacts:
Omega Diagnostics Group PLC | Tel: 01259 763 030 |
Bill Rhodes, Interim Non-Executive Chairman Colin King, Chief Executive | www.omegadiagnostics.com |
Kieron Harbinson, Group Finance Director | |
finnCap Ltd | Tel: 020 7220 0500 |
Geoff Nash/Hannah Boros (Corporate Finance) | |
Camille Gochez (ECM) | |
Walbrook PR Limited | Tel: 020 7933 8780 or [email protected] |
Paul McManus | Mob: 07980 541 893 |
Lianne Cawthorne | Mob: 07584 391 303 |
Related Shares:
ODX.L